Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II…
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or…
CAMBRIDGE, MA / ACCESSWIRE / May 13, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming…
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:…
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the…
COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio…
MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused…
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by…
Surpasses its goal of reaching 25 million women by 2025RAHWAY, NJ / ACCESSWIRE / May 8, 2024 / Merck (NYSE:MRK),…
Surpasses its goal of reaching 25 million women by 2025RAHWAY, NJ / ACCESSWIRE / May 8, 2024 / Merck (NYSE:MRK),…